Inovio Pharmaceuticals Inc

NASDAQ:INO  
12.31
+1.92 (+18.48%)
Regulatory, Other Pre-Announcement

Inovio Reports Third Quarter 2020 Financial Results

Published: 11/09/2020 22:10 GMT
Inovio Pharmaceuticals Inc (INO) - Inovio Reports Third Quarter 2020 Financial Results.
Q3 Earnings per Share $0.11.
Q3 Revenue $236,000 Versus $867,000.
Q3 Revenue Estimate $3 Million -- Refinitiv Ibes Data (analyst estimates).
Q3 Earnings per Share Estimate $-0.19 -- Refinitiv Ibes Data (analyst estimates).
Inovio Pharmaceuticals - Has Responded to FDA to Address Questions Related to Partial Clinical Hold on Inovio's Ind for Phase 2/3 Trial of Ino-4800.
Anticipates a Response From FDA This Month As to Whether Planned Phase 2/3 Clinical Trial of Ino-4800 Can Proceed.
Remain Encouraged by Safety and Tolerability Data of 1no-4800 We Have Observed Thus Far.